Literature DB >> 22147439

Delayed diagnosis of primary hyperparathyroidism in a patient with osteoclastoma.

Daria Baszko-Błaszyk1, Maciej Biczysko, Paweł Gut, Ryszard Waśko, Jerzy Sowiński.   

Abstract

Primary hyperparathyroidism (HPTo) nowadays is most often recognized incidentally in the asymptomatic period as a result of biochemical screening or evaluation of low bone mass. Classical manifestations of the disease are present in about 15-20% of patients. We present the case of a 28-year-old male patient who had been treated for two years for osteoclastoma of the proximal tibia, first by intralesional curettage with cement filling followed by bone grafting, and finally with a reconstructive arthroplasty of the knee joint. The patient had been consulted in different medical centers by at least 14 doctors representing 9 different specialties, but the correct diagnosis of HPTo had not been made, although classic manifestations of the disease had been present for 5-6 years. This suggests that a diagnosis of HPTo is difficult nowadays. Therefore, determination of serum calcium concentration and other markers of calcium and phosphate metabolism should be obligatory in patients with bone lesions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147439     DOI: 10.5604/15093492.967216

Source DB:  PubMed          Journal:  Ortop Traumatol Rehabil        ISSN: 1509-3492


  3 in total

1.  Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor.

Authors:  Barbara Rossi; Virginia Ferraresi; Maria Luisa Appetecchia; Mariangela Novello; Carmine Zoccali
Journal:  Skeletal Radiol       Date:  2013-11-24       Impact factor: 2.199

2.  A patient with multiple brown tumors due to secondary hyperparathyroidism: A case report.

Authors:  Laura Messina; A Garipoli; F M Giordano; U Ferrari; R Grippo; M Sarli; B Beomonte Zobel
Journal:  Radiol Case Rep       Date:  2021-07-02

3.  Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism.

Authors:  Waldemar Misiorowski; Izabela Czajka-Oraniec; Magdalena Kochman; Wojciech Zgliczyński; John P Bilezikian
Journal:  Endocrine       Date:  2017-09-12       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.